Can you take Pemetrexed with Penicillin v potassium?

penicillin V potassium has a moderate potential interaction with Allergies.

Penicillin products should be used with caution in individuals with histories of significant allergies and/or asthma.

penicillin V potassium has a moderate potential interaction with Asthma.

Penicillin products should be used with caution in individuals with histories of significant allergies and/or asthma.

PEMEtrexed has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Pemetrexed can cause severe myelosuppression resulting in the need for transfusion and which may lead to neutropenic infection. The risk of myelosuppression is increased in patients who do not receive vitamin supplementation (including oral folic acid and IM vitamin B12). Patients with myelosuppression should be monitored carefully. A CBC should be obtained at the beginning of each cycle and as needed. Treatment should not be initiated unless the absolute neutrophil count is at least 1500 cells/mm3 and platelet count is at least 100,000 cells/mm3.

PEMEtrexed has a moderate potential interaction with History, Radiation Therapy.

Radiation recall can occur with pemetrexed in patients who have received radiation weeks to years previously. Patients should be monitored for inflammation/blistering in areas of previous radiation treatment; they should be advised to immediately contact their health care provider if inflammation/blisters develop in a previously irradiated area. Pemetrexed should be permanently discontinued for signs of radiation recall.

PEMEtrexed has a moderate potential interaction with Liver Disease.

No formal studies have been conducted to examine pemetrexed in patients with liver dysfunction. Caution is advised.

penicillin V potassium has a major potential interaction with Noninfectious Colitis.

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.

PEMEtrexed has a major potential interaction with Pulmonary Impairment.

Serious interstitial pneumonitis (including fatal case) can occur with pemetrexed. Care should be exercised when using pemetrexed in patients with preexisting pulmonary impairment. Pemetrexed should be withheld for acute onset of new/progressive unexplained pulmonary symptoms; if pneumonitis is confirmed, pemetrexed should be permanently discontinued.

PEMEtrexed has a major potential interaction with Renal Dysfunction.

Pemetrexed can cause severe (and sometimes fatal) renal toxicity. Pemetrexed is primarily eliminated by the kidneys; decreased renal function results in decreased clearance and increased pemetrexed exposure compared with normal renal function. No dose is recommended for patients with CrCl less than 45 mL/min. CrCl should be determined before each dose and renal function should be monitored periodically during therapy. Pemetrexed should be withheld in patients with renal toxicity until CrCl is 45 mL/min or greater.